Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Growth (Status and Outlook) 2020-2025

December 2020 | 118 pages | ID: GF6C5EAB20D1EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

According to this study, over the next five years the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market will register a 7.1%% CAGR in terms of revenue, the global market size will reach $ 6421.6 million by 2025, from $ 4872.4 million in 2019. In particular, this report presents the global revenue market share of key companies in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx), covering the supply chain analysis, impact assessment to the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market size growth rate in several scenarios, and the measures to be undertaken by Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020 in Section 2.3; and forecast to 2025 in section 10.7.

• PCR
• In-situ Hybridization
• Immunohistochemistry
• Sequencing
• Others

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2025 in section 10.8.

• Oncology
• Neurological Disorders
• Cardiovascular Disease
• Immunological Disorders
• Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.

• Qiagen NV
• GE Healthcare
• F Hoffman La Roche
• Foundation Medicine
• Agilent Technologies
• Pfizer
• Thermo Fisher Scientific Inc.
• Leica Biosystems Nussloch GmBH

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

• To study and analyze the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market size by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
• To understand the structure of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market by identifying its various subsegments.
• Focuses on the key global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
• To analyze the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) with respect to individual growth trends, future prospects, and their contribution to the total market.
• To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
• To project the size of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) submarkets, with respect to key regions (along with their respective key countries).
• To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
• To strategically profile the key players and comprehensively analyze their growth strategies.

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2015-2025
  2.1.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size CAGR by Region
2.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Segment by Type
  2.2.1 PCR
  2.2.2 PCR
  2.2.3 Immunohistochemistry
  2.2.4 Sequencing
  2.2.5 Others
2.3 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type
  2.3.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Type (2015-2020)
  2.3.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth Rate by Type (2015-2020)
2.4 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Segment by Application
  2.4.1 Oncology
  2.4.2 Neurological Disorders
  2.4.3 Cardiovascular Disease
  2.4.4 Immunological Disorders
  2.4.5 Others
2.5 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application
  2.5.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Application (2015-2020)
  2.5.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth Rate by Application (2015-2020)

3 GLOBAL PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) BY PLAYERS

3.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Players
  3.1.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Players (2018-2020)
  3.1.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Players (2018-2020)
3.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) BY REGIONS

4.1 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Regions
4.2 Americas Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth
4.3 APAC Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth
4.4 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth
4.5 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth

5 AMERICAS

5.1 Americas Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Countries
5.2 Americas Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type
5.3 Americas Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Regions
6.2 APAC Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type
6.3 APAC Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions

7 EUROPE

7.1 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) by Countries
7.2 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type
7.3 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) by Countries
8.2 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type
8.3 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers and Impact
  9.1.1 Growing Demand from Key Regions
  9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 GLOBAL PHARMACOGENOMICS TECHNOLOGY/THERANOSTICS/COMPANION DIAGNOSTICS (CDX) MARKET FORECAST

10.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Forecast (2021-2025)
10.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Forecast by Regions
  10.2.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Forecast by Regions (2021-2025)
  10.2.2 Americas Market Forecast
  10.2.3 APAC Market Forecast
  10.2.4 Europe Market Forecast
  10.2.5 Middle East & Africa Market Forecast
10.3 Americas Forecast by Countries
  10.3.1 United States Market Forecast
  10.3.2 Canada Market Forecast
  10.3.3 Mexico Market Forecast
  10.3.4 Brazil Market Forecast
10.4 APAC Forecast by Countries
  10.4.1 China Market Forecast
  10.4.2 Japan Market Forecast
  10.4.3 Korea Market Forecast
  10.4.4 Southeast Asia Market Forecast
  10.4.5 India Market Forecast
  10.4.6 Australia Market Forecast
10.5 Europe Forecast by Countries
  10.5.1 Germany Market Forecast
  10.5.2 France Market Forecast
  10.5.3 UK Market Forecast
  10.5.4 Italy Market Forecast
  10.5.5 Russia Market Forecast
  10.5.6 Spain Market Forecast
10.6 Middle East & Africa Forecast by Countries
  10.6.1 Egypt Market Forecast
  10.6.2 South Africa Market Forecast
  10.6.3 Israel Market Forecast
  10.6.4 Turkey Market Forecast
  10.6.5 GCC Countries Market Forecast
10.7 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Forecast by Type
10.8 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Forecast by Application

11 KEY PLAYERS ANALYSIS

11.1 Qiagen NV
  11.1.1 Company Details
  11.1.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Offered
  11.1.3 Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2020)
  11.1.4 Main Business Overview
  11.1.5 Qiagen NV News
11.2 GE Healthcare
  11.2.1 Company Details
  11.2.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Offered
  11.2.3 GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2020)
  11.2.4 Main Business Overview
  11.2.5 GE Healthcare News
11.3 F Hoffman La Roche
  11.3.1 Company Details
  11.3.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Offered
  11.3.3 F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2020)
  11.3.4 Main Business Overview
  11.3.5 F Hoffman La Roche News
11.4 Foundation Medicine
  11.4.1 Company Details
  11.4.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Offered
  11.4.3 Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2020)
  11.4.4 Main Business Overview
  11.4.5 Foundation Medicine News
11.5 Agilent Technologies
  11.5.1 Company Details
  11.5.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Offered
  11.5.3 Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2020)
  11.5.4 Main Business Overview
  11.5.5 Agilent Technologies News
11.6 Pfizer
  11.6.1 Company Details
  11.6.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Offered
  11.6.3 Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2020)
  11.6.4 Main Business Overview
  11.6.5 Pfizer News
11.7 Thermo Fisher Scientific Inc.
  11.7.1 Company Details
  11.7.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Offered
  11.7.3 Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2020)
  11.7.4 Main Business Overview
  11.7.5 Thermo Fisher Scientific Inc. News
11.8 Leica Biosystems Nussloch GmBH
  11.8.1 Company Details
  11.8.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Offered
  11.8.3 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2020)
  11.8.4 Main Business Overview
  11.8.5 Leica Biosystems Nussloch GmBH News

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Research Methodology
Table 2. Data Source
Table 3. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Players of PCR
Table 5. Major Players of In-situ Hybridization
Table 6. Major Players of Immunohistochemistry
Table 7. Major Players of Sequencing
Table 8. Major Players of Others
Table 9. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2014-2019) ($ Millions)
Table 10. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Type (2015-2020)
Table 11. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020) ($ Millions)
Table 12. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Application (2015-2020)
Table 13. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Players (2018-2020) ($ Millions)
Table 14. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Players (2018-2020)
Table 15. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Key Players Head office and Products Offered
Table 16. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Regions 2015-2020 ($ Millions)
Table 20. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Regions 2015-2020
Table 21. Americas Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Countries (2015-2020) ($ Millions)
Table 22. Americas Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Countries (2015-2020)
Table 23. Americas Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020) ($ Millions)
Table 24. Americas Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Type (2015-2020)
Table 25. Americas Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020) ($ Millions)
Table 26. Americas Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Application (2015-2020)
Table 27. APAC Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Regions (2015-2020) ($ Millions)
Table 28. APAC Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Regions (2015-2020)
Table 29. APAC Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020) ($ Millions)
Table 30. APAC Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Type (2015-2020)
Table 31. APAC Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020) ($ Millions)
Table 32. APAC Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Application (2015-2020)
Table 33. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Countries (2015-2020) ($ Millions)
Table 34. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Countries (2015-2020)
Table 35. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020) ($ Millions)
Table 36. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Type (2015-2020)
Table 37. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020) ($ Millions)
Table 38. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Application (2015-2020)
Table 39. Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Countries (2015-2020) ($ Millions)
Table 40. Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Countries (2015-2020)
Table 41. Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020) ($ Millions)
Table 42. Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Type (2015-2020)
Table 43. Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020) ($ Millions)
Table 44. Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Application (2015-2020)
Table 45. Key and Potential Regions of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx)
Table 46. Key Application and Potential Industries of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx)
Table 47. Key Challenges of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx)
Table 48. Key Trends of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx)
Table 49. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Forecast by Regions (2021-2025) ($ Millions)
Table 50. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share Forecast by Regions
Table 51. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Forecast by Type (2021-2025) ($ Millions)
Table 52. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share Forecast by Type (2021-2025)
Table 53. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Forecast by Application (2021-2025) ($ Millions)
Table 54. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share Forecast by Application (2021-2025)
Table 55. Qiagen NV Details, Company Total Revenue (in $ million), Head Office, Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Market Areas and Its Competitors
Table 56. Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Offered
Table 57. Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Gross Margin (2018-2020E)
Table 58. Qiagen NV Main Business
Table 59. Qiagen NV Latest Developments
Table 60. GE Healthcare Details, Company Total Revenue (in $ million), Head Office, Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Market Areas and Its Competitors
Table 61. GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Offered
Table 62. GE Healthcare Main Business
Table 63. GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Gross Margin (2018-2020E)
Table 64. GE Healthcare Latest Developments
Table 65. F Hoffman La Roche Details, Company Total Revenue (in $ million), Head Office, Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Market Areas and Its Competitors
Table 66. F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Offered
Table 67. F Hoffman La Roche Main Business
Table 68. F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Gross Margin (2018-2020E)
Table 69. F Hoffman La Roche Latest Developments
Table 70. Foundation Medicine Details, Company Total Revenue (in $ million), Head Office, Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Market Areas and Its Competitors
Table 71. Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Offered
Table 72. Foundation Medicine Main Business
Table 73. Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Gross Margin (2018-2020E)
Table 74. Foundation Medicine Latest Developments
Table 75. Agilent Technologies Details, Company Total Revenue (in $ million), Head Office, Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Market Areas and Its Competitors
Table 76. Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Offered
Table 77. Agilent Technologies Main Business
Table 78. Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Gross Margin (2018-2020E)
Table 79. Agilent Technologies Latest Developments
Table 80. Pfizer Details, Company Total Revenue (in $ million), Head Office, Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Market Areas and Its Competitors
Table 81. Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Offered
Table 82. Pfizer Main Business
Table 83. Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Gross Margin (2018-2020E)
Table 84. Pfizer Latest Developments
Table 85. Thermo Fisher Scientific Inc. Details, Company Total Revenue (in $ million), Head Office, Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Market Areas and Its Competitors
Table 86. Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Offered
Table 87. Thermo Fisher Scientific Inc. Main Business
Table 88. Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Gross Margin (2018-2020E)
Table 89. Thermo Fisher Scientific Inc. Latest Developments
Table 90. Leica Biosystems Nussloch GmBH Details, Company Total Revenue (in $ million), Head Office, Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Market Areas and Its Competitors
Table 91. Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Offered
Table 92. Leica Biosystems Nussloch GmBH Main Business
Table 93. Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Gross Margin (2018-2020E)
Table 94. Leica Biosystems Nussloch GmBH Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Report Years Considered
Figure 2. Market Research Methodology
Figure 3. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth Rate 2015-2025 ($ Millions)
Figure 4. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Type (2015-2020)
Figure 5. Global PCR Market Size Growth Rate
Figure 6. Global In-situ Hybridization Market Size Growth Rate
Figure 7. Global Immunohistochemistry Market Size Growth Rate
Figure 8. Global Sequencing Market Size Growth Rate
Figure 9. Global Others Market Size Growth Rate
Figure 10. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) in Oncology
Figure 11. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market: Oncology (2015-2020) ($ Millions)
Figure 12. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) in Neurological Disorders
Figure 13. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market: Neurological Disorders (2015-2020) ($ Millions)
Figure 14. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) in Cardiovascular Disease
Figure 15. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market: Cardiovascular Disease (2015-2020) ($ Millions)
Figure 16. Global Cardiovascular Disease YoY Growth ($ Millions)
Figure 17. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) in Immunological Disorders
Figure 18. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market: Immunological Disorders (2015-2020) ($ Millions)
Figure 19. Global Immunological Disorders YoY Growth ($ Millions)
Figure 20. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) in Others
Figure 21. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market: Others (2015-2020) ($ Millions)
Figure 22. Global Others YoY Growth ($ Millions)
Figure 23. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Application in 2019
Figure 24. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Regions 2015-2020
Figure 25. Americas Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2015-2020 ($ Millions)
Figure 26. APAC Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2015-2020 ($ Millions)
Figure 27. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2015-2020 ($ Millions)
Figure 28. Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2015-2020 ($ Millions)
Figure 29. Americas Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Countries in 2019
Figure 30. Americas Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Type in 2019
Figure 31. Americas Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Application in 2019
Figure 32. United States Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth 2015-2020 ($ Millions)
Figure 33. Canada Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth 2015-2020 ($ Millions)
Figure 34. Mexico Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth 2015-2020 ($ Millions)
Figure 35. APAC Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Regions in 2019
Figure 36. APAC Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Type in 2019
Figure 37. APAC Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Application in 2019
Figure 38. China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth 2015-2020 ($ Millions)
Figure 39. Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth 2015-2020 ($ Millions)
Figure 40. Korea Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth 2015-2020 ($ Millions)
Figure 41. Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth 2015-2020 ($ Millions)
Figure 42. India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth 2015-2020 ($ Millions)
Figure 43. Australia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth 2015-2020 ($ Millions)
Figure 44. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Countries in 2019
Figure 45. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Type in 2019
Figure 46. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Application in 2019
Figure 47. Germany Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth 2015-2020 ($ Millions)
Figure 48. France Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth 2015-2020 ($ Millions)
Figure 49. UK Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth 2015-2020 ($ Millions)
Figure 50. Italy Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth 2015-2020 ($ Millions)
Figure 51. Russia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth 2015-2020 ($ Millions)
Figure 52. Spain Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth 2015-2020 ($ Millions)
Figure 53. Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Countries in 2019
Figure 54. Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Type in 2019
Figure 55. Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Market Share by Application in 2019
Figure 56. Egypt Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth 2015-2020 ($ Millions)
Figure 57. South Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth 2015-2020 ($ Millions)
Figure 58. Israel Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth 2015-2020 ($ Millions)
Figure 59. Turkey Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth 2015-2020 ($ Millions)
Figure 60. GCC Countries Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth 2015-2020 ($ Millions)
Figure 61. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) arket Size Forecast (2021-2025) ($ Millions)
Figure 62. Americas Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 63. APAC Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 64. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 65. Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 66. United States Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 67. Canada Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 68. Mexico Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 69. Brazil Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 70. China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 71. Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 72. Korea Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 73. Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 74. India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 75. Australia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 76. Germany Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 77. France Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 78. UK Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 79. Italy Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 80. Russia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 81. Spain Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 82. Egypt Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 83. South Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 84. Israel Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 85. Turkey Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)
Figure 86. GCC Countries Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size 2021-2025 ($ Millions)